Applying Trial Informatics' IT Solutions and Providing Optimized End-to-End Medical Device Clinical ServicesC&R Research has signed a clinical trial agreement with Nova Bio for the medical device study of its biocompatible gum filler, 'SMILELINE'.Through this collaboration, C&R Research will provide end-to-end medical device clinical services and apply IT solutions from Trial Informatics, an AI-based IT solutions company within the C&R Family, to enhance the efficiency and accuracy of clinical data management and analysis.For more details, please refer to the link below.Read the text | Ref: The Yakup News

C&R Research’s website has been honored with the Grand Prize in the Healthcare Services category at the 'Web Award Korea 2025'.The award recognizes the site’s clear visual representation of C&R’s professional expertise, along with its advanced content strategy and highly competitive user experience across the platform. Read the text | Ref: Newspim

  Partnership to develop video data management, analysis, and research solutionsTrial Informatics, a company specializing in AI-based clinical trial IT solutions, announced on the 16th that it signed a memorandum of understanding (MOU) with the Seoul Asan Medical Center Clinical Trial Center on the 15th and established a strategic partnership for the management and analysis of clinical trial image data and the development of research solutions.The two institutions will further strengthen their collaboration in the area of ​​clinical trial image data. Through various activities, including the commissioning and acceptance of imaging-related research projects, they aim to enhance research accuracy and reliability, contributing to the development of the clinical trial industry and future medical innovation. The Seoul Asan Medical Center Clinical Trial Center will be responsible for various image interpretations, while Trial Informatics will handle data management based on an IT platform.  Read the text | Ref: Edaily

C&R Research, Korea's first contract research organization (CRO), recently received two clinical trial approvals (IDE and IND) from the US FDA, solidifying its position as a global clinical partner.C&R Research recently secured two consecutive IDE and IND approvals from the US FDA, demonstrating its global clinical capabilities. First, IMGT's 'IMD10', an access ultrasound system for pancreatic cancer treatment, received FDA IDE (Investigational Device Exemption), laying the foundation for the initiation of clinical trials in the US.  Read the text | Ref: Consumer Times

  Strategic Collaboration with Mediplexus, a Leading Real-World Data SpecialistC&R Research signed an MOU on December 5 with Mediplexus, a specialized Real-World Data (RWD) and Real-World Evidence (RWE) healthcare data company, to strengthen competitiveness in clinical research based on real-world data.Through this collaboration, the two companies aim to strengthen their data, AI, and platform capabilities using hospital-based real-world data, driving innovation and improving clinical research efficiency. This will support C&R Research’s shift toward a ‘Data CRO,’ enabling more integrated services from study design to regulatory and post-marketing support.Moontae Yoon, CEO of C&R Research, stated, “This collaboration marks an important starting point in advancing personalized, data-driven clinical research. It will create new momentum to achieve both patient-centered product design and reductions in research time and cost. By combining the extensive healthcare data and clinical expertise of both organizations, we will establish a differentiated Data CRO business model, set new standards for clinical processes, and lead the future competitiveness of the industry.”  Read the text | Ref: Yakup News

  Global Regulatory Expertise in ADC-Based ModalitiesC&R Research announced that Intocell’s investigational solid tumor therapy, ITC-6146RO, has received FDA approval for its Phase 1 IND application.ITC-6146RO is an innovative anticancer candidate developed using Intocell’s next-generation ADC (Antibody-Drug Conjugate) platform, featuring proprietary linker–payload technology designed to improve drug safety and enhance toxicity management.Throughout the IND review process, C&R Research led CTD strategy and preparation, managed FDA communications, and handled regulatory feedback, demonstrating the company’s strong global regulatory capabilities in the field of advanced biopharmaceuticals.  Read the text | Ref: Hankyung